Tagged with P

healthcare The co-president of a research group dedicated to Euro-Mediterranean health sector issues analyses commonalities across the North African region and calls for a coordinated response to shared challenges. He also delivers a comparative assessment of the Algerian market. What is your opinion about the evolution of the Algerian pharmaceutical industry and…

manufacturing The president of Algeria’s union for pharmaceutical operators discusses the state of the local industry and sheds light on the sets of challenges his members (both importers and domestic manufactures) face under the current context. The state expects a radical change in Algeria’s production makeup, with 70 percent of drug needs…

pharmaceuticals The general manager gives tips on how to succeed in the Algerian market and explains how there is something in it for all types of business. Can you introduce yourself, introduce the CCIAF, and how the Chamber of Commerce has evolved over times?  The CCIAF is a non-profit organization, approved by…

clinical trials The country manager of a British biopharmaceutical company sheds light on Algeria’s potential for conducting clinical trials and offers his views on the quality of the country’s skilled labour. What is the record of your past fourteen months with AstraZeneca? Since I arrived, I have had two priorities. First, I implemented a new…

hospitals Representatives from a French/Austrian consortium that has just been awarded a contract to construct a new University Hospital Centre in Constantine reveal why this sort of turnkey project is highly innovative and represents a landmark moment in the history of Algerian healthcare. Could you please start by introducing your consortium…

manufacturing The founder of one of Algeria’s pioneer pharmaceutical manufacturers tells his story about how he guided his company up the value chain having originally started off by undertaking the packaging component before moving on to  more complex forms. He also discusses the ‘made in Algeria’ brand and the challenges of sourcing skilled…

pharmaceuticals Boehringer Ingelheim is turning 130 in 2015. Miguel Salazar, president and country managing director for Mexico, explains how he is steering the company to bypass the currents of the ever-changing Mexican market to lead the company to enter the top five in the coming future. How has the pharmaceutical industry…

investment Besides protecting the health of Mexicans, COFEPRIS today offers an important value-added to the investment community: predictability. The organization’s commissioner shares the astonishing results of his last three years of tenure, undertaken with the priority of improving access of the population to a well-supplied drug market and making the Mexican…

biotech Biograft is the first private tissue bank in Mexico meeting the increasing demand for implants of human musculoskeletal tissue. The general director and founder discusses the vision behind the creation of Biograft, how the company mastered to overcome skepticism and the plans to expand exports and transform the company in…

pharmaceuticals The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean market look today? The Argentinean market is a solid, mature and competitive business with a lot of potential in biotechnology…

pharmaceutical trade Dr. Valverde, a respected authority on pharmacovigilance from the University of Mamonides, discusses the emerging pharmaceutical trade relationship between China and Argentina in the context of the dynamic Argentinian industry. To begin, would you please introduce the Cámara Argentinos-China? The Argentinian Republic and the People’s Republic of China established trade…

orphan drugs Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing patients. What is the current state of affairs for HoFH patients in Argentina? So far, as lomitapide is not yet…